Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CEL-SCI Corporation (CVM)

2.78   0.06 (2.21%) 02-07 16:00
Open: 2.68 Pre. Close: 2.72
High: 2.7873 Low: 2.65
Volume: 69,588 Market Cap: 121(M)

Technical analysis

as of: 2023-02-07 4:27:32 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 3.63     One year: 4.24
Support: Support1: 2.67    Support2: 2.4
Resistance: Resistance1: 3.1    Resistance2: 3.63
Pivot: 2.73
Moving Average: MA(5): 2.7     MA(20): 2.74
MA(100): 2.95     MA(250): 3.58
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 36.1     %D(3): 28.3
RSI: RSI(14): 55.9
52-week: High: 6.13  Low: 1.87
Average Vol(K): 3-Month: 175 (K)  10-Days: 69 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CVM ] has closed below upper band by 37.3%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.79 - 2.8 2.8 - 2.81
Low: 2.62 - 2.63 2.63 - 2.65
Close: 2.76 - 2.78 2.78 - 2.8

Company Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Headline News

Wed, 08 Feb 2023
Americanas' $4B Accounting Scandal Puts More Scrutiny on PwC's ... - Insurance Journal

Tue, 07 Feb 2023
Light : Notice to the market - Clarification on CVM/B3 inquiries - Marketscreener.com

Tue, 07 Feb 2023
LMU-CVM exhibits at USPC convention - Claiborne Progress - Claiborne Progress

Mon, 06 Feb 2023
Deer may be reservoir for SARS-Cov-2 variants, study suggests - VeterinaryPracticeNews.com

Thu, 02 Feb 2023
Sigma CVM Romania Announces National Distribution Partnership ... - Business Review

Sun, 29 Jan 2023
Norwegian Marine Equipment Supplier Teco 2030 Chooses CVM ... - Hydrogen Central

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 43 (M)
Shares Float 41 (M)
% Held by Insiders 3.8 (%)
% Held by Institutions 38.3 (%)
Shares Short 7,910 (K)
Shares Short P.Month 8,660 (K)

Stock Financials

EPS -0.94
EPS Est Next Qtl 0
EPS Est This Year -0.42
EPS Est Next Year -0.29
Book Value (p.s.) 1.3
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -38.9
Return on Equity (ttm) -96.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.54
Sales Per Share 0
EBITDA (p.s.) -0.79
Qtrly Earnings Growth 0
Operating Cash Flow -19 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -2.99
PEG Ratio 0
Price to Book value 2.12
Price to Sales 0
Price to Cash Flow -6.4

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-06-14
Ex-Dividend Date 1996-08-27
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.